Eagle Capital Growth Fund Inc (GRF)

7.67
AMEX : Financial
Prev Close 7.68
Day Low/High 7.65 / 7.70
52 Wk Low/High 6.91 / 10.20
Avg Volume 7.10K
Exchange AMEX
Shares Outstanding 3.59M
Market Cap 27.56M
EPS 0.90
P/E Ratio 109.71
Div & Yield 1.19 (15.50%)

Latest News

Hologic Completes Divestiture Of Blood Screening Business

Hologic Completes Divestiture Of Blood Screening Business

- Strengthens Efforts to Build a Sustainable Growth Company -

Eagle Capital Growth Fund Finalizes Year-End Distribution Of $1.19 Per Share

Eagle Capital Growth Fund Finalizes Year-End Distribution Of $1.19 Per Share

The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE MKT: GRF) today finalized its year-end distribution of $1.

Cash Dividend On The Way From Eagle Capital Growth Fund (GRF)

Cash Dividend On The Way From Eagle Capital Growth Fund (GRF)

Looking at the universe of stocks we cover at Dividend Channel, on 11/21/16, Eagle Capital Growth Fund Incorporated will trade ex-dividend, for its annual dividend of $1.19, payable on 12/28/16. As a percentage of GRF's recent stock price of $8.76, this dividend works out to approximately 13.59%, so look for shares of Eagle Capital Growth Fund Incorporated to trade 13.59% lower — all else being equal — when GRF shares open for trading on 11/21/16.

Eagle Capital Growth Fund Declares Year-End Distribution Of $1.19 Per Share

Eagle Capital Growth Fund Declares Year-End Distribution Of $1.19 Per Share

The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE MKT: GRF) today declared a year-end distribution of $1.

Grifols Immunohematology Center Laboratory In San Marcos, Texas, Has Expanded Its Testing Capabilities To Include Basic And Advanced Serological And Molecular Testing. (Graphic: Business Wire)

Grifols Immunohematology Center Laboratory In San Marcos, Texas, Has Expanded Its Testing Capabilities To Include Basic And Advanced Serological And Molecular Testing. (Graphic: Business Wire)

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company, has expanded the menu of tests offered at the Grifols Immunohematology Center laboratory to include basic and advanced serological and molecular...

FDA Approves Use Of The Procleix Zika Virus Assay From Hologic And Grifols To Screen The U.S. Blood Supply Under An IND Study Protocol

FDA Approves Use Of The Procleix Zika Virus Assay From Hologic And Grifols To Screen The U.S. Blood Supply Under An IND Study Protocol

­­­­­--Blood banks will use the new test, co-developed by Hologic and Grifols, to screen donated blood in potential endemic areas of the US--

Singulex Announces A $50 Million Investment By Grifols For A 20% Stake In The Company

Singulex Announces A $50 Million Investment By Grifols For A 20% Stake In The Company

Grifols investment to Shape the Future of Blood Screening

Eagle Capital Growth Fund Finalizes Year-End Distribution Of $0.50 Per Share

Eagle Capital Growth Fund Finalizes Year-End Distribution Of $0.50 Per Share

The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE MKT: GRF) today finalized its year-end distribution of $0.

Eagle Capital Growth Fund Declares Year-End Distribution Of $0.50 Per Share

Eagle Capital Growth Fund Declares Year-End Distribution Of $0.50 Per Share

The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE MKT: GRF) today declared a year-end distribution of $0.

Grifols To Make A Major Equity Investment In Alkahest

Grifols To Make A Major Equity Investment In Alkahest

-- Alkahest is a company founded in 2014 by leading scientists who demonstrated at Stanford University (US) that factors in the blood of young animals were able to restore mental capabilities in old animals

Reminder - Eagle Capital Growth Fund (GRF) Goes Ex-Dividend Soon

Reminder - Eagle Capital Growth Fund (GRF) Goes Ex-Dividend Soon

Looking at the universe of stocks we cover at Dividend Channel, on 12/10/14, Eagle Capital Growth Fund Incorporated will trade ex-dividend, for its annual dividend of $0.37, payable on 12/24/14. As a percentage of GRF's recent stock price of $8.30, this dividend works out to approximately 4.46%, so look for shares of Eagle Capital Growth Fund Incorporated to trade 4.46% lower — all else being equal — when GRF shares open for trading on 12/10/14.

Eagle Capital Growth Fund Declares Year-End Distribution Of $0.37 Per Share

Eagle Capital Growth Fund Declares Year-End Distribution Of $0.37 Per Share

The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE MKT: GRF) today declared a year-end cash distribution of $0.

Grifols Celebrates World Hemophilia Day With Donation Of Coagulation Medicines To The World Federation Of Hemophilia

Grifols Celebrates World Hemophilia Day With Donation Of Coagulation Medicines To The World Federation Of Hemophilia

- Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries

Eagle Capital Growth Fund Incorporated About To Put More Money In Your Pocket (GRF)

Eagle Capital Growth Fund Incorporated About To Put More Money In Your Pocket (GRF)

Looking at the universe of stocks we cover at Dividend Channel, on 12/11/13, Eagle Capital Growth Fund Incorporated will trade ex-dividend, for its annual dividend of $1.02, payable on 12/27/13. As a percentage of GRF's recent stock price of $9.06, this dividend works out to approximately 11.26%, so look for shares of Eagle Capital Growth Fund Incorporated to trade 11.26% lower — all else being equal — when GRF shares open for trading on 12/11/13.

Eagle Capital Growth Fund Declares Year-End Distribution Of $1.02 Per Share

Eagle Capital Growth Fund Declares Year-End Distribution Of $1.02 Per Share

The Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE MKT: GRF) today declared a year-end cash distribution of $1.

Grifols Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency

Grifols Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency

Study results presented at annual meeting of American Thoracic Society (ATS)

PROLASTIN® Celebrates 25 Years As Leading Augmentation Therapy For Treatment Of Alpha(1)-antitrypsin Deficiency

PROLASTIN® Celebrates 25 Years As Leading Augmentation Therapy For Treatment Of Alpha(1)-antitrypsin Deficiency

Grifols to commemorate anniversary by sponsoring events and programs to promote awareness and research